Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.77 |
| ▸ | PPARG | P37231 | 8/20 | 0.76 |
| ▸ | PPARA | Q07869 | 8/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | OSBP | P22059 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arachidin-2 SCHEMBL31544968 | 1.00 | MAOA (1.00) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| Arachidin-2 SCHEMBL4742876 | 1.00 | MAOA (1.00) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| SCHEMBL13970532 | 0.87 | CYP19A1 (1.00) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| SCHEMBL24074948 | 0.87 | PPARG (1.00) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| SCHEMBL16200005 | 0.87 | MAOB (0.76) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| Chiricanine A SCHEMBL19717932 | 0.87 | MAOA (0.77) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| SCHEMBL24074947 | 0.87 | MAOA (0.77) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| Schweinfurthin J SCHEMBL31544937 | 0.86 | PPARG (0.97) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| SCHEMBL25223796 | 0.84 | MAOA (0.73) | MAOAMAOBCYP19A1PTGS2ALOX5 | |
| SCHEMBL28185918 | 0.84 | MAOA (0.73) | MAOAMAOBCYP19A1PTGS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072473-A1 | ANTIMICROBIALS AS FEED PRESERVATIVES | IRP Health Pty Ltd (AU) | 2021-04-22 | — | — | WO | claimed |
| EP-1311257-B1 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | INSMED INC (US) | 2005-04-27 | — | — | EP | claimed |
| EP-1311257-A2 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | Insmed Incorporated (US) | 2003-05-21 | — | — | EP | claimed |
| US-6552085-B2 | For lowering blood glucose in a mammal | INSMED INCORPORATED | 2003-04-22 | — | — | US | claimed |
| US-6410596-B1 | FOR LOWERING BLOOD GLUCOSE IN A MAMMAL | INSMED INCORPORATED | 2002-06-25 | — | — | US | claimed |
| US-20020058707-A1 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | INSMED INCORPORATED | 2002-05-16 | — | — | US | claimed |
| US-20020058701-A1 | Compositions containing hypoglycemically active stilbenoids | SHAMAN PHARMACEUTICALS | 2002-05-16 | — | — | US | claimed |
| WO-2002013811-A2 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | INSMED INCORPORATED (US) | 2002-02-21 | — | — | WO | claimed |
| WO-2002014252-A2 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | INSMED INCORPORATED (US) | 2002-02-21 | — | — | WO | claimed |
| WO-2024249297-A2 | POLYMERIC COMPOSITIONS WITH PRENYLATED STILBENES | Cambium Biomaterials, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2021072473-A1 | ANTIMICROBIALS AS FEED PRESERVATIVES | IRP Health Pty Ltd (AU) | 2021-04-22 | — | — | WO | disclosed |
| US-20130209617-A1 | COMPOSITIONS AND METHODS FOR USE IN PROMOTING PRODUCE HEALTH | PACE INTERNATIONAL, LLC (US) | 2013-08-15 | — | — | US | disclosed |
| EP-1311257-B1 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | INSMED INC (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1311258-B1 | COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS | INSMED INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20020058707-A1 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | INSMED INCORPORATED | 2002-05-16 | — | — | US | disclosed |
| US-20020058701-A1 | Compositions containing hypoglycemically active stilbenoids | SHAMAN PHARMACEUTICALS | 2002-05-16 | — | — | US | disclosed |
| US-20020055541-A1 | Compositions containing hypotriglyceridemically active stilbenoids | SHAMAN PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2002013811-A2 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | INSMED INCORPORATED (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002013809-A2 | COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS | INSMED INCORPORATED (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002013806-A2 | COMPOSITIONS CONTAINING HYPOTRIGLYCERIDEMICALLY ACTIVE STILBENOIDS | INSMED INCORPORATED (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058707-A1 | COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS | SLC5A2, SLC5A1, SLC2A1 | MAOA 1094/4885MAOB 844/4885CYP19A1 207/4885 |
| US-20020055541-A1 | Compositions containing hypotriglyceridemically active stilbenoids | CPT1B, CPT1A, LIPC | MAOA 2321/4885MAOB 1218/4885CYP19A1 618/4885 |
| US-20020058701-A1 | Compositions containing hypoglycemically active stilbenoids | SLC5A2, SLC5A1, SLC2A1 | MAOA 1094/4885MAOB 844/4885CYP19A1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.